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a b s t r a c t
NADPH oxidases are the major sources of reactive oxygen species in cardiovascular, neural, and kidney
cells. The NADPH oxidase 5 (NOX5) gene is present in humans but not rodents. Because Nox isoforms in
renal proximal tubules (RPTs) are involved in the pathogenesis of hypertension, we tested the hypothesis
that NOX5 is differentially expressed in RPT cells from normotensive (NT) and hypertensive subjects (HT).
We found that NOX5 mRNA, total NOX5 protein, and apical membrane NOX5 protein were 4.270.7-fold,
5.270.7-fold, and 2.870.5-fold greater in HT than NT. Basal total NADPH oxidase activity was 4.570.2-
fold and basal NOX5 activity in NOX5 immunoprecipitates was 6.270.2-fold greater in HT than NT
(P¼o0.001, n¼6–14/group). Ionomycin increased total NOX and NOX5 activities in RPT cells from HT
(Po0.01, n¼4, ANOVA), effects that were abrogated by pre-treatment of the RPT cells with diphenylene-
iodonium or superoxide dismutase. Silencing NOX5 using NOX5-siRNA decreased NADPH oxidase activity
(45.173.2% vs. mock-siRNA, n¼6–8) in HT. D1-like receptor stimulation decreased NADPH oxidase
activity to a greater extent in NT (32.571.8%) than HT (14.871.8). In contrast to the marked increase
in expression and activity of NOX5 in HT, NOX1 mRNA and protein were minimally increased in HT,
relative to NT; total NOX2 and NOX4 proteins were not different between HT and NT, while the increase
in apical RPT cell membrane NOX1, NOX2, and NOX4 proteins in HT, relative to NT, was much less than
those observed with NOX5. Thus, we demonstrate, for the ﬁrst time, that NOX5 is expressed in human
RPT cells and to greater extent than the other Nox isoforms in HT than NT. We suggest that the increased
expression of NOX5, which may be responsible for the increased oxidative stress in RPT cells in human
essential hypertension, is caused, in part, by a defective renal dopaminergic system.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
The reduced nicotinamide adenine dinucleotide phosphate
(NADPH) oxidases have been studied extensively in phagocytic
and non-phagocytic cells, including those from cardiovascular,
neural, pulmonary, and renal tissues [1–3]. The NADPH oxidase
family, which has seven members, is classiﬁed into three groups:
group 1, comprised of NOX1, NOX2, NOX3, NOX4; group 2,
comprised of NOX5; and group 3, comprised of DOUX1 and
DOUX2 [1]. NADPH oxidase-dependent enzymes are the major
sources of reactive oxygen species (ROS) in non-phagocytic cells,
including cardiovascular, neural, and renal cells [2,4–9]. ROS are
important in intracellular signaling. However, excessive ROS pro-
duction can lead to cell injury and death [2,9,10]. Indeed, oxidative
stress is thought to be important in the pathogenesis of many
diseases, such as cardiovascular and renal diseases and hyperten-
sion [2,4,5,9–11].
Nox1, Nox2, and Nox4 are predominantly expressed in cardio-
vascular and renal tissues in humans and rodents [2,4–8]. The
NOX5 gene, which is present in humans but not rodents [12,13]
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was initially reported to be expressed in human testis, spleen, and
lymph node [14]. More recently, NOX5 has been reported in
human vascular endothelial and smooth muscle cells [9,15–17].
Five splice variants of human NOX5, namely NOX5α, NOX5β,
NOX5γ, NOX5δ, and short NOX5, have been identiﬁed [14,15].
NOX5 differs from the other NADPH oxidase isoforms in that it
contains an N-terminal calmodulin-like domain with four binding
sites for Ca2þ (EF hands) and does not require p22phox or other
subunits for its activation [1,3]. NOX5 can be activated by throm-
bin, platelet-derived growth factor, angiotensin II, endothelin 1,
and protein kinase C [15–22]. NOX5 can also be directly regulated
by intracellular Ca2þ , the binding of which induces a conforma-
tional change, leading to enhanced ROS generation [18–23].
Dopamine is an important regulator of sodium balance and
blood pressure through an independent peripheral dopaminergic
system [11,24,25]. Knockout of any of the dopamine receptor
subtypes (D1R, D2R, D3R, D4R, and D5R) results in hypertension,
the pathogenesis of which is receptor subtype-speciﬁc [24].
D1-like receptor (comprised of D1R and D5R) regulation of renal
proximal tubule (RPT) sodium transport is defective in genetically
hypertensive rats and patients with essential hypertension
[11,24–32]. More speciﬁcally, D1R function is impaired in RPT cells
from humans with essential hypertension [33]. Both decreased
dopamine receptor function and increased ROS production con-
tribute to the pathogenesis of essential hypertension [2,11,24,25].
D1-like receptors inhibit oxidative stress in vascular smooth
muscle and RPT cells [11,28–31]. However, oxidative stress can
also cause dysfunction of D1R in rat RPT cells [32] and ROS
production is increased in RPT cells from spontaneously hyperten-
sive rats (SHRs) [34]. NADPH oxidase activity and protein levels of
Nox2 and Nox4 are greater in kidneys and cerebral arteries of SHRs
than those from their normotensive controls (Sprague-Dawley and
Wistar-Kyoto [WKY]) rats [29–31,35]. We now report for the ﬁrst
time that NOX5 is the predominant NADPH oxidase isoform
expressed in human RPT cells, the expression of which is greater
in RPT cells from hypertensive (HT) than normotensive subjects
(NT). We suggest that increased NOX5 expression and activity may
contribute to the increased oxidative stress in human essential
hypertension.
To read materials and some methods, please see the online
supplement.
Methods
Cell sources and cell culture
RPT cells, from histologically normal sections of human kidneys
freshly obtained from adult normotensive (NT: NT9, NT16, and
NT22) and hypertensive subjects (HT: HT2, HT14, and HT19) who
had unilateral nephrectomy due to renal carcinoma or trauma,
were grown in culture [33]. These cells have been characterized for
D1-like receptor expression and function (i.e., response to dopa-
mine and dopamine receptor agonists and antagonists) [33,36].
The human RPT cells were maintained in phenol-free Dulbecco's
modiﬁed Eagle's medium/F12 medium supplemented with 10%
fetal bovine serum (FBS), epidermal growth factor (10 ng/ml),
ITSTM premix (insulin, transferrin, and selenium), hydrocortisone
(36 ng/ml), triiodothyronine (4 pg/ml), and primocin (500 μg/ml) at
37 1C in humidiﬁed 5% CO2/95% air [31,33,36].
Measurement of NADPH oxidase activity
NADPH oxidase activity was measured in triplicate, using
whole cell membranes in the presence of lucigenin (10 μmol/L)
and NADPH (100 μmol/L), as described previously [8,29,31]. The
dynamic tracings of NADPH oxidase-dependent activity were
recorded for 180 s (AutoLumat Plus luminometer, LB953, EG&G
Berthhold, Germany) and the results expressed as arbitrary light
units (ALU), corrected for protein concentration. We also measured
ROS production in whole cell homogenates, in the presence of
lucigenin (10 μmol/L) and NADPH (100 μmol/L), using a microplate
luminometer (MicroWin 2000). NADPH oxidase activity was
expressed as relative luminescence units (RLU), corrected for
protein concentration. Protein concentrations were determined
by a bicinchoninic acid kit. To compare vehicle and drug treatment
groups, the percentage of the absolute value of each drug treat-
ment relative to the absolute mean of the vehicle-treated controls
was calculated.
In some experiments, calcium-dependent NADPH oxidase
activity in RPT cells was measured [9,18,19,23]. Whole RPT cell
membranes were prepared as described above and membrane
oxidase activity was measured in the absence or presence of CaCl2
(1.0 mmol/L) [9,19,23]. The difference between NADPH oxidase
activity in the absence calcium (total NADPH oxidase activity) and
NADPH oxidase activity in the presence of Ca2þ (NOX5 activity)
represented Ca2þ-independent oxidase activity [9]. The NADPH
oxidase activities were expressed as RLU/50 μg protein and con-
verted to % change of NT as described previously [8,29,31].
Measurement of NOX5 activity in NOX5-immunoprecipitates
Because there is no speciﬁc test for NOX5 activity, we ﬁrst
isolated NOX5 from the other NADPH oxidase isoforms by immu-
noprecipitation, as described under “Materials and Methods”,
Supplementary information. The immunoprecipitates (IPs) were
washed twice with ice-cold PBS and then ﬁnally washed once with
assay buffer. NOX5 assay buffer was reconstituted as described
[9,19,23]. NOX5 activity was measured in duplicate, by incubating
the NOX5 immunoprecipitates with assay buffer (200 μl) contain-
ing 1 PBS buffer, pH 7.4, (mmol/L) 100 KCl, 2 MgCl2, and 1 EGTA,
100 mM FAD (Sigma-Aldrich), in the presence of 1.0 mmol/L CaCl2
and 50 mmol/L lucigenin. The reaction was allowed to proceed for
20 min at 37 1C in a water bath. The supernatants, in duplicate,
were immediately transferred into a 96-well microplate and read
on a luminometer (MicroWin 2000) at 25 1C following the injec-
tion (20 μl) of NADPH (200 μmol/L, ﬁnal concentration) and
monitored for 30 min. Normal rabbit IgG IPs served as negative
controls. NOX5 activity was expressed as relative luminescence
units (RLU) and converted to % of control values [8,29,31]. In some
cases RPT cell membrane NADPH oxidase activity was measured
using the same protocol.
Measurement of extracellular ROS production
Extracellular ROS production was measured in triplicate by the
superoxide dismutase (SOD)-inhibitable reduction of cytochrome c
(absorbance at 550 nm). Cells (5106 cells/well) cultured on 12-
well plates were incubated in 0.5 ml phenol-free DMEM/F12
medium containing reduced cytochrome c (200 μmol/L) with or
without SOD (200 μmol/L) for 15 min at 37 1C. The incubation was
continued for another 30 min in the presence of vehicle or the D1-
like receptor agonist, fenoldopam (1 mmol/L), and the absorbance
of reduced cytochrome c was measured at 550 nm optical density
(OD), using a Victor spectrophotometer (PerkinElmer Life, Shelton,
CT). SOD-inhibitable reduction of cytochrome c was calculated by
the formula [nmol¼159 (ODSODODþSOD)] [37,38]. The
results were expressed as nmol/5106 cells. To compare vehicle
and drug treatment groups, the percentage of the absolute value of
each drug treatment relative to the absolute mean of the vehicle-
treated controls was calculated.
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Measurement of ROS production in live RPT cells by a ﬂuorogenic
probe
Cells were initially grown on coverslips in DMEM/F12 complete
medium. The medium was then changed to phenol-free DMEM/
F12 medium containing 1% dialyzed FBS and the ﬂuorogenic probe
CellROS Deep Red reagent (5 μmol/L, ﬁnal concentration) and
incubated for 30 min at 37 1C. The cells were washed with PBS
buffer three times, ﬁxed with 4% paraformaldehyde in PBS buffer
for 10 min, and mounted on coverslips using ProLongs Gold
reagent. ROS ﬂuorescence images were obtained using laser
confocal scanning microscopy (Zeiss LSM 510) at excitation/emis-
sion wavelengths of 644/655 nm at 630x magniﬁcation. Using ZEN
2012 software NOX5 was colored green, ROS was colored red, and
the merged image was yellow. In some cases 5-(and-6)-carboxy-
2',7'-dichloroﬂuorescein diacetate (carboxy-DCFDA) was also used
to measure ROS production (“Materials and Methods”,
Supplementary information).
Real-time quantitative PCR
Total RNA was extracted from RPT cells with the RNeasy Mini
Kit (Qiagen Inc., Valencia, CA) and reverse transcription (RT) was
performed using M-MLV reverse transcriptase (Invitrogen). Two
micro liters of the RT product was used for real-time PCR (SYBR
Green qPCR Supermix UDG Kit, Invitrogen): 50 1C for 2 min and
95 1C for 10 min, followed by 40 cycles at 95 1C for 15 s and 63 1C
for 60 s. The human NOX5 primers were 5'-AACTTCTG-
GAAGTGGCTGCT-3' (sense, nt #1251-71), and 5'-GAGGAGATGAGT-
GACCTTGGA-3' (antisense, nt # 1376-86). Human GAPDH primers
were 5'-GTCGTGGAGTCTACTGGCGTCTT-3' (sense), and 5'-
CAGTCTTCTGAGTGGCAGTGATGG-3' (antisense). Expression of the
target gene was normalized against the expression of GAPDH (ABI
Prism 7700 sequence detector system, Applied Biosystems, SDS
(Ver. 1.91, Foster City, CA).
Statistical analysis
Numerical data were expressed as mean7standard error of the
mean (SEM). Signiﬁcant difference between two groups was
determined by the Student's t-test. Signiﬁcant differences among
groups (42) were determined by one-way factorial ANOVA
followed by the Newman–Keuls test. Po0.05 was considered
signiﬁcant.
Results
Expression of NOX5 mRNA
Previous studies have shown that mRNA and protein levels of
Nox isoforms (Nox2, and Nox4) are greater in RPT cells from SHRs
than WKY rats [31,39,40]; Nox1, Nox2, and Nox4 expressions are
also increased in vascular smooth muscles cells of SHRs [4]. In the
current report, we determined which NADPH oxidase isoform
contributed to the enhanced NADPH oxidase activity in RPT cells
from HT, relative to NT. In contrast to the studies in rats, we found
that in human RPT cells, NOX2 and NOX4 mRNAs were similar in
NT and HT. In agreement with the studies in vascular smooth
muscle cells of SHRs [4], NOX1 mRNA was greater in HT than NT
(Supplementary Fig. S1). The mRNA expression of NOX5, which is
found in humans but not rodents, was also greater in HT (3.570.1
fold) than NT (1.070.2) (Fig. 1A). The increased basal NOX5 mRNA
in HT relative to NT was veriﬁed by real-time qPCR; NOX5 mRNA
was 4.270.7-fold greater in HT than NT (Po0.001, vs. NT, n¼4,
t-test) (Fig. 1B).
Protein proﬁle of NADPH oxidase isoforms in Human RPT cells
Except for NOX3 and DUOX, the ﬁve other NOX isoforms are
ubiquitously expressed in tissues and organs of humans. NOX1,
NOX2, and NOX4 proteins, which are present in RPT cells from
humans [8] and rats, are expressed to a greater extent in SHRs
than WKY rats [4,31,39,40]. We, therefore, determined whether or
not NADPH oxidase isoform protein expression is also greater in
RPT cells from hypertensive than normotensive humans (i.e., HT
vs. NT). In agreement with the mRNA data, total cellular NOX2 and
NOX4 proteins were similar in NT and HT (Fig. 2A and B), while
total cellular NOX1 protein was slightly greater in HT (1.270.-fold)
than NT (P¼0.016) (Fig. 2A and B). By contrast, total cellular NOX5
protein was markedly greater in HT (5.270.7-fold) than NT
(Fig. 2A and B). Similar results were obtained using four other
RPT cell lines from HT (n¼2) and NT (n¼2) (Fig. S2, supplemen-
tary ﬁle). NOX3 protein was not found in human RPT cells, in
agreement with a previous report [13]. We also studied the effect
of the number of cell passages on NOX5 mRNA expression, NOX5
protein, and ROS production (6 vs. 20 passages). NOX5 expression
and ROS production were not different after 6 or 20 passages of HT
cells (Fig. S3 supplementary ﬁle). In addition, 3 pairs of human RPT
primary cells (4–10 passages) were studied for NOX5 protein
expression and activity. In these lower passaged RPT cells, NOX5
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Fig. 1. Expression of NOX5 mRNA in human RPT cells. (A). RT-PCR analysis of
human NOX5mRNA in RPT cells from normotensive (NT) and hypertensive subjects
(HT). The results were normalized with β–ACTIN mRNA, converted to % of NT, and
shown as mean7SEM. nPo0.01 vs. NT, n¼4, t-test. Two of four experiments are
shown above the bar graphs. (B). Real-time quantitative PCR analysis of human
NOX5 mRNA in human RPT cells. Reverse transcription (RT) utilized M-MLV reverse
transcriptase and real-time quantitative PCR used the SYBR Green qPCR Supermix
system. Results were normalized with GAPDH mRNA, converted to % of NT and
shown as mean7SEM. nPo0.01 vs. NT, n¼4, t-test.
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protein was also greater in HT than NT (Fig. S4A, supplementary
ﬁle); ROS production was also greater in HT (349791% of NT) than
NT cells (10073.0) (Fig. S4B, supplementary ﬁle).
Apical and basolateral membrane localization of NADPH oxidase
isoform proteins
NOX5 was found in the perinuclear region and plasma mem-
brane in human endothelial cells [15] and NOX5-transfected
human embryonic kidney (HEK) 293 cells [20,21]. In RPT cells
from NT, endogenous NOX5 was localized to a greater extent at the
perinuclear area and to a lesser extent at the cell membrane
(Fig. 3A, upper panel). In contrast, in RPT cells from HT, NOX5 was
predominantly localized at the cell membrane but was present
also in the cytosol and nucleus and co-localized with ROS (Fig. 3A,
lower panel, and Fig. S5 supplementary ﬁle). ROS production was
abrogated by pretreatment of the HT cells with the NADPH oxidase
inhibitor, diphenyleneiodonium (DPI), and superoxide dismutase
(SOD) which dismutates superoxide to hydrogen peroxide
(Fig. 3B). The presence of NOX5 protein at the RPT cell membrane
in HT was conﬁrmed by biotinylation studies (Fig. S6, supplemen-
tary ﬁle). We quantiﬁed the protein levels of NOX isoforms (NOX1,
2, 4, and 5) at the apical membrane by cell surface biotinylation,
immunoprecipitation, and immunoblotting with speciﬁc anti-NOX
isoform antibodies. NOX1, NOX2, and NOX4 proteins were
expressed to a greater extent in apical than basolateral membranes
of RPT cells from both NT and HT (Fig. 3C and D). Furthermore,
NOX1, NOX2, NOX4, and NOX5 protein levels were greater in the
apical membranes of RPT cells from HT than NT; NOX5 protein, in
particular, was 2.870.5-fold greater in HT than NT (Fig. 3C and D,
and Table S1, supplementary ﬁle). Thus, while total cellular NOX1
and NOX5 proteins but not NOX2 and NOX4 were greater in RPT
cells from HT than NT, apical membrane expressions of NOX1,
NOX2, NOX4, and NOX5 were all increased in HT relative to NT.
However, of these NOX isoforms, the total cellular and apical
membrane expression of NOX5 was increased to a greater extent
than the other NOX isoforms in HT, relative to NT.
NADPH oxidase activity and ROS production
We used four different methods to measure NADPH oxidase
activity and/or ROS production in RPT cells. First, total NADPH
oxidase activity was measured in the presence of lucigenin and
NADPH using whole cell membranes (Fig. 4A), as reported pre-
viously [8,31]. We have previously reported that basal NADPH
oxidase activity was greater in RPT cells from SHRs than fromWKY
rats [31]. In the current study, basal total NADPH oxidase activity
was also greater in RPT cells from HT (4.570.2-fold) than NT
(Fig. 4A). In contrast, the D1-like receptor agonist fenoldopam,
using a concentration that is less than the Vmax [29], decreased
NADPH oxidase activity to a greater extent in RPT cells from NT
(32.571.8%) than HT (14.871.8%) (Po0.01, t-test) (Fig. 4B).
The effect of fenoldopam was speciﬁc to the D1-like receptor
because the inhibitory effect of fenoldopam on NADPH oxidase
activity was reversed by the addition of the D1-like receptor
antagonist Sch23390 in both NT and HT (Fig. 4B).
Calcium-dependent NADPH oxidase activity in total cell mem-
branes was measured in the presence of 1.0 mmol/L CaCl2 since
NOX5 is a calcium-dependent enzyme [9,14,18,19,23]. NADPH
oxidase activity expressed % control (no ionomycin) or RLUs is
shown in Fig. S7A and B in the supplementary ﬁle. As shown in
Fig. 4C, Left ﬁgure, calcium-independent NADPH oxidase activity
was 2.370.3-fold greater in HT (230733%) than NT cells
(10071.6%) (P¼0.003). However, calcium-dependent NADPH oxi-
dase activity was even greater (3.670.7-fold) in HT (362735%)
than NT (10077.6%) (P¼0.001) (Fig. 4C, right ﬁgure).
NOX5 is a calcium-dependent enzyme and ionomycin, which
raises the intracellular level of Ca2þ , stimulates NOX5 activity
[9,14,18,19]. Therefore, we studied the effect of ionomycin on
NOX5 activity using whole cell membranes from HT cells only
because NOX5 protein expression was minimally expressed in NT
cells (Figs. 1 and 2). Ionomycin stimulated NADPH oxidase activity
only in the presence of calcium (Fig. S7A, supplementary ﬁle) [18].
Ionomycin increased membrane NADPH oxidase activity
(þ127.376.0% vs. 100.671.8%, vehicle control) (P¼0.008, vs.
control, ANOVA) (Fig. 4D). The stimulatory effect of ionomycin
on NADPH oxidase activity was decreased below control values by
SOD, or DPI.
Second, NOX5-speciﬁc oxidase activity was measured in immu-
noprecipitated NOX5 in the presence of CaCl2. In HT and NT cells
(4–18 passages) NOX5 activity in NOX5 immunoprecipitates was
2791.97200.7 RLU in HT vs. 432.37128.5 RLU in NT (P¼0.003),
Table S2, supplementary ﬁle). Fig. 5A, left ﬁgure, shows that basal
NOX5 activity (measured immediately after the injection of
NADPH, in the presence of calcium) was 6.2-fold greater in HT
(624725% of NT) than NT (10074%) (Po0.001, t-test, n¼6–14).
The amount of NOX5 pulled down (Fig. S8 supplementary ﬁle) was
also greater in HT (24475%) than NT (10272%) (P¼0.03). Fig. 5A,
right ﬁgure shows the NOX5 activity monitored over a period of
30 min. Following the injection of NADPH, NOX5 activity increased
with the time, peaked at 10 min and started to decline at 15 min.
Fig. 5B shows that in HT cells, ionomycin increased NOX5 activity
by 2576.3% compared with control (vehicle-treatment) (Po0.01
vs. control, one-way ANOVA). The effect of ionomycin on NOX5
activity was abrogated by pre-treatment of HT cells with either DPI
or SOD, both of which decreased NOX5 activity below control
values, similar to those observed for total NADPH oxidase activity
(Fig. 4D).
Third, extracellular ROS production was measured by SOD-
inhibitable reduction of cytochrome c in live RPT cells [19–21,37,38].
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To evaluate the relationship between the localization of the NOX
isoforms at the apical membranes and extracellular ROS production,
we measured extracellular ROS production using the SOD-inhibitable
reduction of cytochrome c. We found that extracellular ROS
production was 2.6-fold greater in HT (45.972.0 nmol/5106
cells) than NT (18.473.5 nmol/5106 cells) (Fig. 5C) (Po0.001,
one-way ANOVA, Newman–Keuls test, n¼5/group). D1-like recep-
tor function, assessed by production of cAMP or inhibition of
sodium transporter or pump activity, is impaired in kidney tissues
and cells from humans with essential hypertension and SHRs
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conjugated streptavidin, and the biotinylated protein bands were visualized by ECL reagents. One of 4–5 separate experiments is shown. (D). Quantiﬁcation of NOX isoform
proteins in apical membranes of human RPT cells. The immunoreactive bands of apical membranes (AP) shown in Fig. 3C and those in the other 4–5 experiments were
quantiﬁed by densitometry, as described under “Section 2”. The results were expressed as % of NT and shown as mean7SEM of 4–5/groups, nPo0.05, vs. NT, t-test.
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[31–33, 36, 40]. These previous reports were corroborated by the
current studies in that the D1-like receptor agonist fenoldopam
decreased ROS production to a greater extent in NT (39.175.8)
than HT (17.172.6) (Fig. 5C), in agreement with its decreased
ability to inhibit NADPH oxidase activity in HT (Fig. 4B).
Finally, we used a ﬂuorescence kit to label live RPT cells and
visualized ROS production by confocal microscopy. The ﬂuores-
cence intensity, measured under the same microscope setting,
was much stronger in RPT cells from HT than NT, indicating that
basal ROS production was greater in HT than NT (Fig. 5D),
corroborating the results using the other methods to measure
ROS production (Figs. 4A, C, and 5C). The ﬁnding that NOX5 co-
localized with ROS in RPT cells from HT (Fig. 3A and Fig. S5)
indicated that intracellular ROS abundance was related to NOX5
protein abundance.
Effect of knockdown of NOX5 expression on NADPH oxidase activity
To determine if the increased NOX5 activity in RPT cells from
HT was causal of the increased ROS production, we measured
NADPH oxidase activity following the silencing of NOX5, using
NOX5-siRNA. Because NOX5 protein in NT cells was barely
detectable (Fig. 3A, Figs. S2, S4 and S5), only RPT cells from HT
were used in the silencing experiments. To determine whether or
not loss of NOX5 expression altered cellular behavior, cell number
was measured following the silencing of NOX5with NOX5-siRNA in
HT cells. Silencing NOX5 decreased NOX5 protein by 5679%
(Fig. 6A) but did not alter cell number (Figs. S9A and B, supple-
mentary ﬁle). In another set of studies, NOX5 protein expression
was decreased by 4076.2% (data not shown) and NADPH
oxidase activity was decreased by 4573.2% (Fig. 6B) in NOX5-
siRNA treated HT RPT cells, relative to mock-siRNA-treated HT RPT
cells. NOX5 activity was also measured with or without ionomycin
following the silencing of NOX5 gene. Ionomycin increased NOX5
activity to a greater extent in mock-silenced (mock-siRNA) HT cells
(þ31.372.8%) than in NOX5-silenced (NOX5-siRNA) HT cells
(þ14.673.2%) (Po0.02, ANOVA) (n¼6) (Fig. 6C); SOD or DPI
decreased NADPH oxidase activity in both mock-siRNA and NOX5-
siRNA-treated RPT cells, to levels below control values, similar to
HT cells not treated with NOX5-siRNA (Fig. 5B).
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Fig. 4. Measurement of NADPH oxidase activity in human RPT cells. (A). Measurement of NADPH oxidase activity in whole cell membranes of human RPT cells. RPT cells, from
normotensive (NT) and hypertensive subjects (HT), grown to 90% conﬂuence and pre-starved in serum-free DMEM/F12 medium (SFM) for 1 h, were treated for 20 min at
37 1C with vehicle (Con), the D1-like receptor agonist fenoldopam (Fen, 1.0 μmol/L), the D1-like receptor antagonist Sch23390 (Sch, 5.0 μmol/L) alone, or a combination of
both antagonist and agonist (SþF); Sch was added to the cells 5 min prior to the addition of fenoldopam. Whole cell membranes were prepared and NADPH oxidase activity
was measured in the presence of 10 μmol/L lucigenin and 100 μmol/L NADPH as described under “Section 2”. NADPH oxidase activity is expressed as arbitrary light units
(ALU) per 50 μg protein. The upper ﬁgures show the dynamic tracings of NADPH oxidase-dependent chemiluminescence recorded over a period of 180 s. The lower ﬁgure
shows basal NADPH oxidase activity expressed as % of NT and shown as mean7SEM (n¼4–7/group). Po0.001, vs. NT, t-test. (B). Summary of NADPH oxidase activity from
the studies shown in Fig. 4A. NADPH oxidase activity was calculated and converted to % of control (Con). Values are mean7SEM of 4–7 separate experiments per group.
nPo0.001, vs. others, # Po0.05 vs. Fen-HT, one-way ANOVA, Newman–Keuls test. (C). Measurement of calcium-independent and calcium-dependent NADPH oxidase
activity in RPT cells. Whole cell membranes were prepared as described under “Section 2”. NADPH oxidase activity was measured in the absence or presence of CaCl2
(1.0 mmol/L). The calcium-independent (left ﬁgure) and -dependent (right ﬁgure) NADPH oxidase activities were expressed as RLU/50 μg protein (Fig. S7B) and expressed as
% of NT (Fig. 4C). Values are mean7SEM (n¼8–12/group), nP¼0.003 for left panel, and nP¼0.001 for right panel, vs. NT, t-test. (D). Effect of ionomycin on NADPH oxidase
activity in RPT cells from HT. RPT cells from HT were pre-treated with vehicle (VEH), superoxide dismutase (SOD, 400 units/ml), or diphenyleneiodonium (DPI, 30 μmol/L) for
45 min. The cells were then treated with vehicle (VEHþVEH, control [Con]) or ionomycin (ION, 1 mmol/L) (VEHþ ION, SODþ ION, DPIþ ION) for an additional 15 min in the
presence of 0.65 mmol/L CaCl2 (equivalent to 47 mmol/L of free Ca2þ) (18). The cell pellets were collected and whole cell membranes were prepared as in Fig. 4A. NADPH
oxidase activity was measured using a microplate luminometer as described under “Section 2”. NADPH oxidase activity was expressed as % of control and shown as
mean7SEM (n¼4/group). nP¼0.008, vs. all others, #Po0.001, vs. SODþ ION and DPIþ ION, one-way ANOVA, Newman–Keuls test.
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Fig. 5. Measurement of NOX5 activity and extracellular ROS production in RPT cells. (A). Measurement of NOX5 activity in RPT cells. Left ﬁgure shows basal NOX5 activity in
NOX5 immunoprecipitates of RPT cells from normotensive (NT) and hypertensive subjects (HT). Human RPT cells were lysed as described under “Section 2”. The cell lysates
were immunoprecipitated with polyclonal anti-NOX5 antibody. NOX5-dependent oxidase activity was measured by incubating the NOX5-immunoprecipitates with assay
buffer in the presence of CaCl2 (1.0 mmol/L), lucigenin (50 μmol/L) and NADPH (200 μmol/L) using a microplate luminometer, as described under “Section 2”. The ﬁrst
readings, which were obtained immediately following the injection of NADPH (ﬁnal concentration¼200 μmol/L), represented basal NOX5 activity (left ﬁgure). NOX5 activity
was calculated and expressed as RLU and converted to % of NT. Values are mean7SEM of 6–14/groups, nP¼o0.001, vs. NT, t-test. Right ﬁgure shows the NOX5 activity
monitored for a period of 30 min following the injection of NADPH, in the presence of calcium. Values are mean7SEM of 6–14/groups, nPo0.001, vs. NT, #Po0.001, vs. all
other time points, one way ANOVA, Newman–Keuls test. (B). Effect of ionomycin on NOX5 activity in HT cells. Cells were pre-treated with vehicle (VEH), ION (ionomycin),
SOD (superoxide dismutase), or DPI (diphenyleneiodonium) as described in Fig. 4D. The cell lysates were subjected to immunoprecipitation and NOX5 activity was measured
as in Fig. 5A. Values are mean7SEM of 4/groups, nPo0.01, vs. other groups, #Po0.001, vs. SODþ ION and DPIþ ION, one-way ANOVA, Newman–Keuls test. (C). Measurement
of extracellular ROS production in RPT cells. Extracellular ROS production was measured by SOD-inhibitable reduction of cytochrome c in live RPT cells. Cells, cultured on 12-
well plates (5106/well), were incubated in 0.5 ml phenol-free DMEM/F12 medium containing reduced cytochrome c (200 μmol/L) with or without SOD (200 μmol/L) for
15 min at 37 1C. The incubation was continued for another 30 min in the presence of vehicle (control, Con) or fenoldopam (Fen, 1 mmol/L). The absorbance of reduced
cytochrome c was measured at 550 nm, and SOD-inhibitable reduction of cytochrome c was calculated (37). The upper ﬁgure shows ROS production expressed as nmol/
5106 cells and the lower ﬁgure shows values expressed as % of Con. Values are mean7SEM of 5/group. Upper panel: nPo0.05, vs. Con (NT or HT), $Po0.01, vs. NT Con,
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test. (D). Visualization of ROS in live cells. ROS were labeled in live cells with CellROS Deep Red ﬂuorogenic probe and visualized by confocal microscopy. Cells, grown on
coverslips, were incubated in phenol-free DMEM/F12, containing 1% dialyzed FBS with ﬂuorogenic probe at a ﬁnal concentration 5 μmol/L for 30 min at 37 1C. The coverslips
were washed, ﬁxed, and mounted as described under “Section 2”. NT cells served as control for HT cells. ROS (triplicate: 1, 2, 3) were detected by confocal microscopy
(excitation and emission wave lengths at 640 and 655 nm, respectively) at 630 magniﬁcation.
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Discussion
The role of NOX isoforms in physiological and pathological
states is well documented. However, studies of NOX5 are relatively
rare because this gene is not found in rodents [12,13]. By contrast,
the NOX5 gene is present in humans and its protein is expressed in
fetal [13] and non-fetal organs and tissues, including the lung,
testis, spleen [14], and vascular endothelial, smooth muscle
[3,7,9,10,15–17,41], and gastrointestinal [42] cells. We now show
for the ﬁrst time that NOX5 mRNA and protein are expressed in
human RPT cells.
NADPH oxidase enzymes are the major sources of ROS produc-
tion in renal and cardiovascular tissues [2,4–9]. The increased
generation of ROS contributes to human [10,11] and animal
hypertension [2,4,5,10,29–32,43]. NADPH oxidase activity and
superoxide formation are increased in endothelial [2,10,41,43],
neural [5,43], renal [2,29–32,43,44], and vascular smooth muscle
cells [4,28,41,43] in genetic and acquired hypertension. Of the Nox
isoforms that are present in rodents (Nox1, Nox2, and Nox4) [2,7–
9,29–32,39], Nox4 has been claimed to be the major NADPH
oxidase in renal [6,43], vascular smooth muscle [4,7,41,43], and
endothelial cells [41,43], and its expression is markedly increased
in hypertensive rodents [2,31,35,43]. It has also been reported that
injection of siRNA against-NOX2 or NOX4 into the hypothalamic
paraventricular nucleus attenuates the development of aldoster-
one/salt-induced hypertension [5]. Therefore, Nox4 may play vital
role in the pathogenesis of animal hypertension. By contrast,
human microvascular endothelial cells possess functionally active
NOX5 which generates ROS and is regulated by angiotensin II and
endothelin 1 [14–16,41]. In patients with coronary artery disease,
NOX5 protein and mRNA levels and NADPH oxidase-dependent
production of ROS in coronary arterial membranes are increased [9].
We now report for the ﬁrst time that NADPH oxidase activity and
mRNA and total cellular protein expressions of NOX5 and NOX1, but
not NOX2 and NOX4 are increased in RPT cells from HT relative
to NT. We also report that the apical membrane expressions of
NOX1, NOX2, NOX4, and NOX5 are increased in RPT cells from HT
relative to NT. However, the increase in NOX5 expression in HT is
greater than the other NOX isoforms. Moreover, the increase
in NOX5 expression and activity in HT is associated with increased
production of ROS. Therefore, we speculate that increased
NOX5 expression may be important in the pathogenesis of human
essential hypertension.
The increase in NOX proteins, especially NOX5 at the apical and
plasma membranes in RPT cells from HT, is associated with
increased extracellular ROS production. This may be related to
polybasic domains within the N-terminus of NOX5, that can bind
phosphatidylinositol 4,5- bisphosphate at the plasma membrane,
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Fig. 6. Effect of silencing of NOX5 gene on NOX5 protein and NADPH oxidase activity in RPT cells from HT. (A). Effect of silencing of NOX5 gene on NOX5 protein expression.
RPT cells from hypertensive subjects (HT) were transfected with vehicle (Con) that contained only transfection reagent, mock siRNA (aka control-siRNA) that consisted of
scrambled RNA and served as a negative control, or NOX5-siRNA for 48 h described under “Section 2”. Cell lysates were immunoblotted with polyclonal anti-NOX5 antibody.
The immunoreactive bands were semi-quantiﬁed and expressed as density units. Values are mean7SEM (n¼6/group). nPo 0.05, vs. others, one-way ANOVA, Newman–
Keuls test. One set of studies is shown on top of the bar graphs. (B). Effect of silencing NOX5 gene on basal NADPH oxidase activity. RPT cells were transfected with vehicle
(Con), mock-siRNA, or NOX5-siRNA for 48 h, as in the Fig. 6A. NADPH oxidase activity was measured in whole cell homogenates in the presence of lucigenin (10 μmol/L) and
NADPH (200 μmol/L) using a microplate luminometer, as described under “Section 2”. The activity, expressed as RLU/mg protein, was converted to % of Con. Values are
mean7SEM of 6/groups, nPo0.001, vs. others, one-way ANOVA, Newman–Keuls test. (C). Effect of ionomycin on NADPH oxidase activity in NOX5-siRNA-treated HT cells.
Cells were transferred with mock-siRNA or NOX5-siRNA for 48 h as in Fig. 6A and B. The cells were treated with vehicle (VEH, Con), ionomycin (ION), superoxide dismutase
(SOD), or diphenyleneiodonium (DPI), as described in Figs. 4D and 5B. NADPH oxidase activity was measured as in Fig. 6B. Values are mean7SEM of 6/groups, nPo0.001, vs.
others, #Po0.001, vs. DPI and SOD, one one-way ANOVA, Newman–Keuls test.
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and promote the trafﬁcking and cell surface expression of NOX5
[20,21]. NOX5 in the endoplasmic reticulum and nucleus may also
contribute to intracellular ROS production [20,21,23]. The coloca-
lization of NOX5 with ROS in RPT cells from HT could be taken to
indicate that the increased intracellular ROS in HT is related to
NOX5 protein abundance.
NOX5 protein is expressed predominantly in the plasma
membrane and to a lesser extent in the cytosol and nucleus.
NOX1-5 proteins have been reported to be expressed in many
subcellular areas, including the nucleus in human endocardial and
vascular endothelial, vascular smooth muscle, esophageal adeno-
carcinoma, prostate cancer, and leukemia cells [18,41,42,44,45].
In agreement with these reports, confocal imaging shows that
NOX5 protein and ROS colocalize in the plasma membrane and
nucleus of RPT cells from HT. Therefore, nuclear NOX5-dependent
ROS production may also contribute to total cellular oxidative
stress. Whether or not nuclear NOX5 is involved in redox respon-
sive gene expression remains to be determined [44].
Ionomycin, an ionophore that increases intracellular Ca2þ and
NADPH oxidase activity [14,18,19], also stimulates NOX5 activity in
HT cells. The stimulatory effect of ionomycin on ROS production is
abrogated by DPI, an NADPH oxidase inhibitor, and SOD which
catalyzes the dismutation of superoxide to H2O2. These data
support the notion that activation of NOX5 is responsible for the
increase in ROS production, speciﬁcally superoxide. There are at
least ﬁve splice variants of NOX5 (α, β, δ, γ, and ε) [15,23].
Ionomycin stimulates NOX5α and β but not the other NOX5
isoforms to produce superoxide [23]. It remains to be determined
whether these NOX5 isoforms are responsible for the increased
ROS production in RPT cells from HT or NOX5 polymorphisms, if
they exist, are associated with the hypertensive phenotype. Never-
theless, increased NOX5 expression and activity are likely to be
important in the increased ROS production in RPT cells from HT
because silencing of NOX5 with siRNA decreases basal NADPH
oxidase activity in RPT cells from HT.
We and others have previously reported that ROS production is
negatively regulated by D1-like receptors in RPT cells from humans
[8] and RPT and vascular smooth muscle cells from rats [28–32].
The inhibitory effect of fenoldopam, a D1-like receptor agonist, on
NADPH oxidase activity is probably exerted at the D1-like receptor
because a D1-like receptor antagonist, Sch23390, blocks the
fenoldopam effect. The decreased ability of fenoldopam to inhibit
NADPH oxidase activity in HT relative to NT is in agreement with
our previous report that fenoldopam inhibits NADPH oxidase
activity to a lesser extent in RPT cells from SHRs than those from
normotensive WKY rats [31]. A defective D1-like receptor may
have caused the impaired ability of fenoldopam to inhibit NADPH
oxidase activity in the RPT cells from HT. We and others have
reported a decreased ability of D1-like receptors to inhibit RPT
sodium reabsorption [27], and stimulate cAMP production and
inhibit sodium transport in RPT cells from hypertensive humans
[33], three animal models of hypertension [11,24,32], and obese
hypertensive rats [46]. The impairment in renal proximal tubular
D1-like receptor function in hypertension is caused by constitutive
phosphorylation of D1R, as a consequence of increased activity of
type 2 and type 4 G protein-coupled receptor kinases
[24,33,46,47].
In conclusion, we report for the ﬁrst time that NOX5 is the
predominant NOX isoform expressed in human RPT cells and its
expression and activity in RPT cells are increased in humans with
essential hypertension. Although the latter conclusion is limited by
the small number of subjects (three normotensive and three hyper-
tensive subjects), NOX5 expression in RPT cells was always greater in
HT than in NT. Thus, it is likely that increased NOX5 expression and
activity may be responsible for the oxidative stress that contributes
to the pathogenesis of human essential hypertension.
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